Quantitative revenue estimates and qualitative assessments of innovative fundraising sources for treating rare diseases in Colombia.

Q2 Medicine
Surrey M Walton, Wilson Mayorga, Angela Rodríguez Narváez, Maria Alejandra Chavez, Natalia Cortés Guesguán, Luis Durango, Ludy Alexandra Parada
{"title":"Quantitative revenue estimates and qualitative assessments of innovative fundraising sources for treating rare diseases in Colombia.","authors":"Surrey M Walton,&nbsp;Wilson Mayorga,&nbsp;Angela Rodríguez Narváez,&nbsp;Maria Alejandra Chavez,&nbsp;Natalia Cortés Guesguán,&nbsp;Luis Durango,&nbsp;Ludy Alexandra Parada","doi":"10.1080/20016689.2023.2211868","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Like many developing countries, Colombia faces difficulties in financing health-care services as well as programs for health promotion and health education and there is evidence that its health-care system is underperforming. <b>Objective:</b> To provide evidence-based estimates of potential funding levels and assess the strengths, weaknesses, and viability of innovative funding mechanisms with a focus on treating rare diseases in Colombia. <b>Methods:</b> The strategy involved evidence-based projections of potential funding levels and a qualitative viability assessment using an expert panel. <b>Results:</b> Crowdfunding, corporate donation, and social impact bonds (SIBs) were deemed to be the most viable of numerous potential strategies. Expected funding levels over 10 years for rare diseases in Colombia from crowdfunding, corporate donations, and SIBs were roughly $7,200, $23,000, and $12,400, respectively. <b>Conclusions:</b> Based on the combination of projected funding potential along with expert consensus regarding viability and operability, crowdfunding, corporate donations, and SIBs, especially in combination, have the potential to substantially improve funding for vulnerable patient populations in Colombia.</p>","PeriodicalId":73811,"journal":{"name":"Journal of market access & health policy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8c/e8/ZJMA_11_2211868.PMC10177688.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of market access & health policy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20016689.2023.2211868","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Like many developing countries, Colombia faces difficulties in financing health-care services as well as programs for health promotion and health education and there is evidence that its health-care system is underperforming. Objective: To provide evidence-based estimates of potential funding levels and assess the strengths, weaknesses, and viability of innovative funding mechanisms with a focus on treating rare diseases in Colombia. Methods: The strategy involved evidence-based projections of potential funding levels and a qualitative viability assessment using an expert panel. Results: Crowdfunding, corporate donation, and social impact bonds (SIBs) were deemed to be the most viable of numerous potential strategies. Expected funding levels over 10 years for rare diseases in Colombia from crowdfunding, corporate donations, and SIBs were roughly $7,200, $23,000, and $12,400, respectively. Conclusions: Based on the combination of projected funding potential along with expert consensus regarding viability and operability, crowdfunding, corporate donations, and SIBs, especially in combination, have the potential to substantially improve funding for vulnerable patient populations in Colombia.

对哥伦比亚治疗罕见疾病的创新筹资来源进行定量收入估计和定性评估。
背景:与许多发展中国家一样,哥伦比亚在资助卫生保健服务以及健康促进和健康教育项目方面面临困难,有证据表明其卫生保健系统表现不佳。目标:对哥伦比亚的潜在供资水平提供基于证据的估计,并评估以治疗罕见疾病为重点的创新供资机制的优势、劣势和可行性。方法:该策略包括以证据为基础的潜在资助水平预测和使用专家小组进行定性可行性评估。结果:众筹、企业捐赠和社会影响债券(sib)被认为是众多潜在策略中最可行的。预计未来10年,哥伦比亚从众筹、企业捐赠和sib获得的罕见病资金水平分别约为7 200美元、23 000美元和12 400美元。结论:基于预测的资金潜力以及专家对可行性和可操作性的共识,众筹、企业捐赠和sib,特别是结合起来,有可能大幅改善哥伦比亚弱势患者群体的资金。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.90
自引率
0.00%
发文量
0
审稿时长
14 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信